Navigation Links
Cellectis Unveils Its New Corporate Website
Date:9/22/2010

PARIS, Sept. 22 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced the launch of its new corporate website. Visitors to this new website are ensured an enhanced usability and information sharing, including more streamlined access to technology and product-related information.

The new Cellectis website focuses on three central themes:

  • Research and Technologies
  • Business Development
  • Investor relations.

In addition to these key areas, the website offers new features and fresh content including:

  • Several specific RSS feeds which enables users to monitor the Company's business in real time, choosing only the subjects they are interested in
  • Social media links (Facebook and Twitter)
  • Downloadable documents that explains Cellectis' technology.

Founded in 1999 by Andre Choulika, PhD and David Sourdive, PhD, Cellectis today has a workforce of over 120 people and 4 subsidiaries, including one located in the U.S. Due to a steady increase in business over the past several months, Cellectis decided to offer its web visitors a showcase that presents the Company' businesses, products and achievements in the most comprehensive manner possible.

Other highlights include the following:

  • A glossary, containing all definitions required to keep up-to-date with Cellectis' activities
  • A graphic library available to qualified journalists, which includes photographs of Cellectis' products and facilities, classified by theme. Journalists need only to register to access and download the files.

The new website can be accessed at: www.cellectis.com.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Follow our news on Twitter: twitter.com/cellectis.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
2. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
5. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
6. iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010
7. ClearTrial Unveils New Product Release at Partnerships in Clinical Trials Conference 2010
8. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
9. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
10. Brooks Instrument Unveils New Web site
11. North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):